Transition Therapeutics Inc (TTHI.OQ) Quote| Reuters.com
Edition:
United States

Transition Therapeutics Inc (TTHI.OQ)

TTHI.OQ on NASDAQ Stock Exchange Global Market

0.70USD
27 Jun 2016
Change (% chg)

$-0.04 (-5.41%)
Prev Close
$0.74
Open
$0.73
Day's High
$0.75
Day's Low
$0.70
Volume
9,261
Avg. Vol
6,396
52-wk High
$2.74
52-wk Low
$0.70

TTHI.OQ

Chart for TTHI.OQ

About

Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the... (more)

Overall

Beta: 1.85
Market Cap(Mil.): $27.66
Shares Outstanding(Mil.): 38.88
Dividend: --
Yield (%): --

Financials

  TTHI.OQ Industry Sector
P/E (TTM): -- 32.69 34.11
EPS (TTM): -0.49 -- --
ROI: -57.41 15.00 14.23
ROE: -64.11 16.08 15.46

BRIEF-Transition Therapeutics reports Q3 loss per share $0.11

* Existing cash resources should enable co to execute business plan and meet projected cash requirements beyond next 12 months Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 11 2016

BRIEF-Transition Therapeutics Q3 loss per share C$0.11

* Q3 loss per share C$0.11 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 11 2016

BRIEF-Transition Therapeutics provides update on type 2 diabetes drug candidate

* Transition therapeutics provides update on type 2 diabetes drug candidate TT401

Apr 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.